Ammoun, Sylwia <br/><br/>
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2.  [electronic resource] 

 -  Journal of neurology, neurosurgery, and psychiatry  10 2019 
 - 1184-1187 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-330X 
<br/><br/><label>Standard No.: </label>10.1136/jnnp-2018-319713  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--metabolism<br/>Blotting, Western<br/>Caspase 3--drug effects<br/>Cyclin D1--drug effects<br/>Humans<br/>Immunohistochemistry<br/>Leukocytes, Mononuclear--drug effects<br/>Mitogen-Activated Protein Kinase 1--drug effects<br/>Mitogen-Activated Protein Kinase 3--drug effects<br/>Molecular Targeted Therapy<br/>Neurofibromatosis 2--drug therapy<br/>Proto-Oncogene Proteins c-akt--drug effects<br/>Receptor, Platelet-Derived Growth Factor beta--drug effects<br/>Ribosomal Protein S6--drug effects<br/>Sorafenib--metabolism